A detailed history of Washington Capital Management Inc transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Washington Capital Management Inc holds 6,500 shares of BMRN stock, worth $551,655. This represents 0.46% of its overall portfolio holdings.

Number of Shares
6,500
Previous 6,500 -0.0%
Holding current value
$551,655
Previous $567,000 5.64%
% of portfolio
0.46%
Previous 0.47%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Sep 18, 2023

SELL
$80.93 - $108.63 $137,581 - $184,671
-1,700 Reduced 20.73%
6,500 $672,000
Q3 2021

Sep 18, 2023

BUY
$74.77 - $85.47 $613,114 - $700,854
8,200 New
8,200 $633,000
Q3 2020

Nov 05, 2020

BUY
$71.87 - $131.03 $122,179 - $222,751
1,700 Added 26.15%
8,200 $624,000
Q4 2019

Feb 07, 2020

BUY
$64.27 - $86.37 $186,383 - $250,473
2,900 Added 80.56%
6,500 $550,000
Q2 2019

Aug 07, 2019

BUY
$80.35 - $93.9 $289,260 - $338,040
3,600 New
3,600 $308,000

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $15.8B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Washington Capital Management Inc Portfolio

Follow Washington Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Washington Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Washington Capital Management Inc with notifications on news.